Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxycholic acid
2019-001015-23Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) comparing Bezafibrate + ursodeoxycholic acid with Placebo + ursodeoxycholic acid (2 arms). Primary endpoint: Primary composite biochemical and liver stiffness response at 24 months. Started Jun 2020; status: active.
02
Drugs
bezafibrate
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2019-001015-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001015-23.